
Opinion|Videos|December 8, 2023
EMERALD Subgroup Analysis in Patients with Coexisting PIK3CA and TP53 Mutations
Author(s)Hope S. Rugo, MD
Dr. Hope Rugo discusses EMERALD subgroup analysis, safety, and efficacy in patients with coexisting resistance mutations.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
3
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5









































